I would think the most attractive things about TTNP to a Pharma buyer would be T3 and Parkinsons. The buyer could own the rights to those drugs and deliver (sell) it themselves. Malaria as well potentially.
Probuphine, the kappa opioid agonist and the mu receptor antagonist are all collaberations that will hopefully involve a nice income stream, buy nobody wants to just buy royalties.
Not sure about Type 2 Diabetes...they haven't said anything about a partner, but I assume there is someone in the background waiting the results of the feasibility study.
News 
Market Data 
Discover 
AI
